271 results on '"Córdoba, Raúl"'
Search Results
2. Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC)
3. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
4. Cellular therapies in older adults with hematological malignancies: A case-based, state-of-the-art review
5. Priorities in Cardio-Oncology Basic and Translational Science: GCOS 2023 Symposium Proceedings: JACC: CardioOncology State-of-the-Art Review
6. Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings
7. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
8. Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry
9. Multidisciplinary Onco-Geriatric Care Models
10. The Spanish Scientific Societies before the ESC 2021 guidelines on vascular disease prevention: Generalizing the measurement of albuminuria to identify vascular risk and prevent vascular disease
11. Artículo especial por el Día Mundial del Riñón: Las sociedades científicas españolas ante la guía ESC 2021 de prevención de la enfermedad vascular: generalizar la medida de la albuminuria para identificar el riesgo vascular y prevenir la enfermedad vascular
12. MOLNUPIRAVIR COMPARED TO NIRMATRELVIR/RITONAVIR FOR COVID-19 IN HIGH-RISK PATIENTS WITH HAEMATOLOGICAL MALIGNANCY IN EUROPE. A MATCHED-PAIRED ANALYSIS FROM THE EPICOVIDEHA REGISTRY
13. Urticarial mycosis fungoides: A distinctive presentation with blood involvement and a peculiar immunophenotype
14. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
15. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
16. Geriatric assessment in older adults with non-Hodgkin lymphoma: A Young International Society of Geriatric Oncology (YSIOG) review paper
17. The Health Impacts of Better Access to Axicabtagene Ciloleucel: The Case of Spain.
18. Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers
19. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study
20. Comparing R-Bendamustine vs. R-CHOP Plus Maintenance Therapy as First-Line Systemic Treatment in Follicular Lymphoma: A Multicenter Retrospective GELTAMO Study
21. Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma
22. A comprehensive approach to therapy of haematological malignancies in older patients
23. Chronic Myelogenous Leukemia and Myeloproliferative Disorders in Older Adults
24. Estratificación, monitorización y control del riesgo cardiovascular en pacientes con cáncer. Documento de consenso de SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC y AECC
25. Histiocytic hyperplasia with hemophagocytosis and acute alveolar damage in COVID-19 infection
26. Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task force
27. European Society of Cardiology Core Curriculum for cardio‐oncology.
28. New therapies for relapsed or refractory aggressive B‐cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group.
29. European Society of Cardiology Core Curriculum for Cardio‐Oncology
30. Current Approach in the Management of Secondary Immunodeficiency in Patients with Hematological Malignancies: Spanish Expert Consensus Recommendations
31. RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group
32. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
33. ABCL-452 First-Line Treatment With Subcutaneous Epcoritamab + R-CHOP in Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL): Phase 1/2 Data Update
34. ABCL-439 Subcutaneous Epcoritamab With Gemcitabine + Oxaliplatin (GemOx) Induced High Response Rates in Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Ineligible for Autologous Stem Cell Transplant (ASCT)
35. Genomic profiling of primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder and angioimmunoblastic T-cell lymphoma
36. Implementing a Broad Digital Framework to Drive Network Strategy Through PROMs and PREMs
37. Peripheral T‐cell lymphoma with a T follicular‐helper phenotype: A different entity? Results of the Spanish Real‐T study.
38. Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers
39. The Spectrum of EBV-positive Mucocutaneous Ulcer: A Study of 9 Cases
40. NanoString analysis of Mycosis Fungoides reveals individual molecular identity
41. P-154 - Genomic profiling of primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder and angioimmunoblastic T-cell lymphoma
42. Atypical Histiocytic Lesion Preceding a Peripheral T-Cell Lymphoma Involving the Skin Exhibiting the Same Molecular Alterations
43. Low‐risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study.
44. Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2.
45. TCL-394 Valemetostat for Patients With R/R Peripheral T-Cell Lymphomas (PTCLs): A Phase 2 VALENTINE-PTCL01 Trial
46. ABCL-272 Epcoritamab + R-DHAX/C Induces Deep, Durable Responses in Transplant-Eligible Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL), Including High-Risk Disease
47. ABCL-275 Epcoritamab + GemOx Induces Deep Durable Responses in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Updated Results From EPCORE NHL-2
48. Valemetostat for Patients With R/R Peripheral T-Cell Lymphomas (PTCLs): A Phase 2 VALENTINE-PTCL01 Trial
49. Epcoritamab + GemOx Induces Deep, Durable Responses in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Updated Results From EPCORE NHL-2
50. Epcoritamab + R-DHAX/C Induces Deep, Durable Responses in Transplant-Eligible Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL), Including High-Risk Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.